Skip to main content

Table 2 Comparison of baseline characteristics in treatment-naïve metastatic renal cell carcinoma patients treated with pazopanib by occurrence of pazopanib-induced hypertension

From: Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Patient Characteristics Total Cohort (N = 35) Pazopanib-induced HTN (N = 20) No Pazopanib-induced HTN (N = 15) P-value
Male Gender 20 (57) 12 (60) 8 (53) 0.697
Age, years 61.9 ± 9.1 62.8 ± 10.4 60.7 ± 7.2 0.479
Pazopanib Therapy
Initial dose 800 mg QD 32 (91) 18 (90) 14 (93) 1
Initial dose 400 mg QD 3 (9) 2 (10) 1 (7) 1
Dose reduction 6 (17) 6 (30) 0 (0) 0.027
Tumor Histology
Clear cell 28 (80) 17 (85) 11 (73) 0.693
Papillary 4 (11) 2 (10) 2 (13) 0.712
Poorly differentiated 3 (9) 1 (5) 2 (13) 0.849
ECOG PS
0 8 (23) 7 (35) 1 (7) 0.101
1 19 (54) 10 (50) 9 (60) 0.734
≥2 8 (23) 3 (15) 5 (33) 0.246
Nephrectomy 22 (63) 12 (60) 10 (67) 0.687
Heart Failure 2 (6) 1 (5) 1 (7) 1
LV Dysfunction 7 (20) 2 (10) 5 (33) 0.112
Diabetes Mellitus 15 (43) 9 (45) 6 (40) 0.775
Hypertension 21 (60) 14 (70) 7 (47) 0.173
Systolic BP, mm Hg 126.9 ± 10.8 130.5 ± 10.9 121.7 ± 8.2 0.010
Diastolic BP, mm Hg 72.3 ± 7.4 74.4 ± 8.5 69.7 ± 4.4 0.045
Dyslipidemia 17 (49) 10 (50) 7 (47) 0.851
GFR < 60 mL/min/1.73 m2 20 (57) 11 (55) 9 (60) 0.767
CAD/PAD 5 (14) 2 (10) 3 (20) 0.631
CVA/TIA 3 (9) 3 (15) 0 (0) 0.244
Thromboembolism 7 (20) 3 (15) 4 (27) 0.430
Smoker 21 (60) 14 (70) 7 (47) 0.297
BMI, kg/m2 29.4 ± 8.7 28.8 ± 6.8 30.2 ± 11.0 0.680
ACEIs/ARBs 14 (40) 11 (55) 3 (20) 0.046
Beta Blockers 11 (31) 5 (25) 6 (40) 0.467
Diuretics 7 (20) 5 (25) 2 (13) 0.672
CCBs 9 (26) 7 (35) 2 (13) 0.244
Statin 13 (37) 8 (40) 5 (33) 0.737
Deceased 15 (43) 9 (45) 6 (40) 0.767
Follow-up time, months 10.0 [3.1-19.4] 11.7 [4.2-20.9] 6.9 [2.1-17.7] 0.257
  1. HTN hypertension, QD once daily, ECOG Eastern Cooperative Oncology Group performance status, LV left ventricular, BP blood pressure, GFR glomerular filtration rate, CAD/PAD coronary artery disease/peripheral arterial disease, CVA/TIA cerebrovascular accident/transient ischemic attack, BMI body mass index, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCBs calcium channel blocker. Data presented as a number with percent (%), mean ± standard deviation, or median [1st quartile-3rd quartile]